Valuation: BioNxt Solutions Inc.

Market Cap 40.83M 28.86M 25.66M 23.78M 21.64M 2.74B 41.48M 286M 112M 1.43B 108M 106M 4.56B P/E 2024
-7.97x
P/E 2025 -10.8x
Enterprise Value 46.72M 33.03M 29.36M 27.21M 24.76M 3.13B 47.47M 327M 128M 1.64B 124M 121M 5.21B EV / Sales 2024
1,754x
EV / Sales 2025 -
Free-Float
94.67%
Yield 2024 *
-
Yield 2025 -
08-28 BioNxt Solutions Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-08 BioNxt Solutions Advances GLP-1 Sublingual Semaglutide Oral Dissolvable Film Program With Next Stage Of Delivery Development Underway CI
06-22 BioNxt Solutions Inc. announced that it has received CAD 2 million in funding CI
06-11 BioNxt Solutions Inc. announced that it expects to receive CAD 2 million in funding CI
05-29 BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-20 BioNxt Solutions Inc Signs Exclusive Negotiation Framework for Potential Commercialization of Cladribine Oral Thin Film Product in Eurasian Patent Organization Member States CI
05-20 BioNxt Solutions Inc Initiates GMP Manufacturing Of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis CI
05-20 BioNxt Solutions Inc. Evaluates Application of Proprietary Drug Delivery Technologies to Psychedelic Therapeutics CI
05-20 BioNxt Solutions Inc. Advances Semaglutide Oral Dissolvable Film Program into Active Pharmaceutical Development CI
05-20 Bionxt Solutions Inc Advances Semaglutide Oral Thin-Film Program and Glp-1 Odf Platform Strategy CI
05-20 BioNxt Solutions Inc. Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform CI
04-29 BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-28 BioNxt Solutions Inc. Auditor Raises 'Going Concern' Doubt CI
1 week-7.69%
Current month-14.29%
1 month-23.08%
3 months-14.29%
6 months-38.78%
Current year-53.12%
1 week 0.3
Extreme 0.3
0.32
1 month 0.3
Extreme 0.3
0.41
Current year 0.28
Extreme 0.28
0.69
1 year 0.28
Extreme 0.28
0.87
3 years 0
Extreme 0
1.1
5 years 0
Extreme 0
1.7
10 years 0
Extreme 0
3.55
Manager TitleAgeSince
Chief Executive Officer 45 2017-12-11
Chief Executive Officer 46 2017-12-11
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 46 2017-12-11
Director/Board Member 60 2018-12-09
Director/Board Member 45 2017-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
7/31/26 Option

Director

100,000 0.0769%
7/31/26 Option

Chief Financial Officer

100,000 0.0769%
7/31/26 Option

Founder

650,000 0.5000%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.69%-64.29%+20.00% 28.86M
+0.43%+6.59%+53.41%+103.85% 1,120B
+0.90%-2.25%+33.02%+62.23% 616B
+0.71%+3.24%+25.81%+93.86% 504B
-0.13%+5.98%+32.91%+50.39% 367B
+0.52%+0.24%+73.92%+40.15% 360B
-0.95%+4.70%+19.51%+43.00% 288B
-1.98%+3.73%-0.86%+13.43% 258B
-0.35%+4.25%+46.21%+50.76% 234B
-0.75%+3.32%+32.53%+97.21% 194B
Average -0.16%+2.48%+25.22%+57.49% 394.09B
Weighted average by Cap. +0.13%+3.83%+39.18%+71.44%

Financials

2024 2025
Net sales 26.98K 19.08K 16.96K 15.72K 14.3K 1.81M 27.42K 189K 74.07K 945K 71.6K 70.07K 3.01M -
Net income -5.31M -3.75M -3.34M -3.09M -2.81M -356M -5.4M -37.19M -14.58M -186M -14.09M -13.79M -593M -7.03M -4.97M -4.41M -4.09M -3.72M -471M -7.14M -49.19M -19.29M -246M -18.64M -18.24M -784M
Net Debt 4.25M 3M 2.67M 2.47M 2.25M 285M 4.32M 29.74M 11.66M 149M 11.27M 11.03M 474M 5.89M 4.17M 3.7M 3.43M 3.12M 395M 5.99M 41.25M 16.17M 206M 15.63M 15.3M 658M
Projected Income Statement - Annual - BioNxt Solutions Inc.
Logo BioNxt Solutions Inc.
BioNxt Solutions Inc. is a Canada-based bioscience company. The Company focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).
Employees
-
Date Price Change Volume
26-10-16 $0.3000 0.00% 6,000
26-10-14 $0.3000 0.00% 54,500
26-10-13 $0.3000 -7.69% 44,500
26-10-09 $0.3250 -1.52% 6,000
  1. Stock Market
  2. Stocks
  3. BNXT Stock